Stereotaxis (STXS)
(Delayed Data from AMEX)
$1.82 USD
+0.06 (3.41%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $1.78 -0.04 (-2.20%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
STXS 1.82 +0.06(3.41%)
Will STXS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for STXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STXS
Stereotaxis (STXS) Gets CE Recertification for Approved Products
Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias
STXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stereotaxis (STXS) Inks Deal to Buy Access Point Technologies
Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
Other News for STXS
Hyliion Holdings And 3 Other Penny Stocks Insiders Are Buying
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment
Stereotaxis announces first heart rhythm treatments at Penn Presbyterian
Stereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory Framework
Stereotaxis receives CE mark recertification under EU’s MDR regulatory framework